Quest Diagnostics has announced the release of three new sexually transmitted disease laboratory test packages that are easy to operate and are accessible to consumers digitally.
Abbott announced an agreement with Johns Hopkins University, the University of Missouri-Kansas City (UMKC), the National Institute of Allergy and Infectious Diseases (NIAID), and the Universite Protestante au Congo (UPC), which resulted in the identification of a group of rare HIV carriers in a patient who had no symptoms.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4461
Published Date: Feb 14, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising cases of STD, sexual harassment, reimbursement schemes for STD testing and treatment and rising population of young adults are few factors likely to drive the market growth.
The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2023-2033.
Possibility of negative impact on the environment, disrupted supply chain owing to COVID-19, and lack of awareness and proper investment are estimated to be the growth hindering factors for the market expansion.
The market in the Asia Pacific region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.
The major players in the market are F. Hoffmann-La Roche Ltd., Abbott, bioMerieux, Becton Dickinson and Company, Quest Diagnostics, Thermo Fisher Scientific, Hologic Inc., Orasure Technologies, Inc., S&P Global, DiaSorin Molecular LLC., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by disease, location, device, and by region.
The laboratory segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.